
ELAN Stock Forecast & Price Target
ELAN Analyst Ratings
Bulls say
Elanco Animal Health demonstrates a strong market position with Simparica Trio leading the market with over 50% share and Credelio Quattro projected to increase its market share to 16.8% by 2026. Additionally, key product lines such as the Advantage Family and Seresto exhibit impressive year-over-year growth, with increases of 33% and 28% respectively in the third quarter of 2025. These trends reflect robust demand for Elanco's offerings and indicate a positive trajectory for the company's financial performance.
Bears say
Elanco Animal Health faces significant challenges that contribute to a negative outlook, primarily due to potential refinancing risks that could adversely affect earnings growth in 2026. Although the company’s revenue has increased by approximately 50%, the EBITDA margin has deteriorated by a few hundred basis points, suggesting a decline in profitability. Furthermore, while the recent EBITDA outperformance of $28 million in the second quarter indicates some operational strength, the overall financial trajectory remains concerning given the backdrop of rising financing costs and margin compression.
This aggregate rating is based on analysts' research of Elanco Animal Health Inc and is not a guaranteed prediction by Public.com or investment advice.
ELAN Analyst Forecast & Price Prediction
Start investing in ELAN
Order type
Buy in
Order amount
Est. shares
0 shares